Health Care · Biological Products, (No Diagnostic Substances)

INMB Inmune Bio, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 171175474 filings
Russell 2000

INMB at a glance

Inmune Bio, Inc. (INMB, SEC CIK 1711754) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on October 29, 2026 and Form 4 insider filings as recently as September 23, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Inmune Bio, Inc. (INMB) reported revenue of $50,000 (up 257.1% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$1.86.
  • As of September 30, 2026, 17 institutional investment managers tracked by SignalX reported holding Inmune Bio, Inc. (INMB) shares worth $5.3 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$50K
+257.1% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
17 funds
$5.3M · −3 vs prior quarter
Latest 8-K
Oct 29, 2026
Item 7.01 · Item 1.01 · Item 3.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Q3 revenue $0, unchanged YoY; net loss $4.7M vs $6.5M
  • Q3 operating expenses $5.0M vs $7.4M, research and development $3.2M vs $4.9M
  • CORDStrom/INKmune costs $2.4M vs $1.1M, highest product-program spending
  • Cash $16.3M at September 30, 2026 vs $24.8M at December 31, 2025; operating cash use $10.0M
  • Near-term headwind: cash projected insufficient for one year; MAA targeted February 2027, BLA mid-2027

AI summary of the INMB 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 29, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • $4.50 million gross financing through 3,000,000 shares and warrants for 3,000,000 shares
  • Warrant exercise price $1.65, exercisable after six months and expiring 5.5 years after issuance

Item 7.01: Regulation FD Disclosure

  • October 28, 2026 press release announced pricing of Inmune Bio’s offering
  • Offering terms and investor dilution implications require review of Exhibit 99.1

Item 1.01: Entry into a Material Definitive Agreement

  • $4.5M gross capital raise through 3M shares at $1.50, strengthening funding before fees and expenses
  • Warrants for 3M additional shares at $1.65, creating potential dilution through April 27, 2032

Item 3.02: Unregistered Sales of Equity Securities

  • Unregistered Common Warrants and underlying shares issued under Section 4(a)(2) private-placement exemption
  • Securities issued to an accredited investor or qualified institutional buyer
Filed Oct 21, 2026Full analysis →

Item 8.01: Other Events

  • Uniphar agreement establishes infrastructure for international access, distribution and commercialization of Ebstrocel
  • Pre-MAA package submitted to UK MHRA for Ebstrocel, advancing regulatory review toward potential UK authorization

Item EX-99.1: Item EX-99.1

  • Master Services Agreement with Uniphar establishes international access, distribution and commercialization infrastructure for Ebstrocel
  • Initial strategy: named-patient access in selected European and MENA markets before local marketing approvals

Item EX-99.2: Item EX-99.2

  • Final pre-MAA package submitted to UK MHRA on October 20, 2026 for Ebstrocel in RDEB
  • Full UK marketing application targeted for early February 2027, potentially advancing approval by approximately six weeks

Item EX-99.3: Item EX-99.3

  • Investor presentation highlights two late-stage platforms: Ebstrocel for RDEB and XPro1595 for inflammation-driven diseases
  • Ebstrocel UK MAA targeted February 2027, potential approval mid-2027, with U.S. BLA planned Q2 2027

Item 7.01: Regulation FD Disclosure

  • Investor presentation furnished as Exhibit 99.3 for use in upcoming company presentations
  • Presentation may provide supplementary information on INmune Bio’s strategy, programs, or outlook
Filed Sep 14, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded to seven directors with additions of R. Duane Clark II and James Sapirstein
  • Both appointees classified independent under Nasdaq Listing Rule 5605

Item 8.01: Other Events

  • Board appointments of Mr. Clark and Mr. Sapirstein announced September 14, 2026
  • Governance expansion potentially relevant to strategic oversight and shareholder confidence

Item EX-99.1: Item EX-99.1

  • Board appointments of R. Duane Clark II and James Sapirstein add rare-disease commercialization and biopharma transaction expertise
  • Clark’s Sanofi rare-disease leadership supports Ebstrocel™ market access, pricing, patient identification and launch planning

AI summaries of INMB 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for INMB

Don't miss the next INMB filing

  • Alerts as it files. A push when INMB files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut INMB, by share count.
  • Ask anything. An AI agent that reads every INMB filing and answers with sources.

INMB alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
SAPIRSTEIN JAMESASep 15, 2026-
Clark Ronnie DuaneASep 15, 2026-
Juda ScottMJul 2, 2026$1.40
Juda ScottXJul 2, 2026$0.13
Lowdell Mark WilliamMJul 2, 2026$1.40
Lowdell Mark WilliamXJul 2, 2026$0.13
Moss David JMJul 2, 2026$1.40
Moss David JXJul 2, 2026$0.13

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$155K$14K$50K
Operating Income--$42.6M-$47.4M
Net Income-$30.0M-$42.1M-$45.9M
Op. Margin--304535.7%-94766.0%
Net Margin-19360.0%-300585.7%-91866.0%
Balance Sheet
Total Assets$57.0M$39.6M$32.4M
Equity-$32.1M$23.5M
ROE--131.1%-195.3%
Per Share
EPS$-1.67$-2.11$-1.86
Cash Flow
Operating CF-$12.0M-$33.4M-$22.6M
CapEx--$1.0M

Source: XBRL data in Inmune Bio, Inc. (INMB)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate INMB share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
INMB shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202617$5.3M
Q2 202620$4.3M
Q1 202618$3.9M
Q4 202517$5.2M
Q3 202517$7.3M
Q2 202518$9.5M
Q1 202516$17.8M
Q4 202413$10.8M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 136 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

INMB filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 5, 2026Analysis
8-KOct 29, 2026Analysis-
8-KOct 21, 2026Analysis-
4Sep 23, 2026--
4Sep 17, 2026--
8-KSep 14, 2026Analysis-
10-QAug 6, 2026Analysis
8-KJul 31, 2026Analysis-
4Jul 7, 2026--
4Jul 7, 2026--
4Jul 7, 2026--
8-KJul 1, 2026Analysis-
8-KJun 23, 2026Analysis-
8-KJun 17, 2026Analysis-
8-KJun 2, 2026Analysis
8-KMay 14, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 5, 2026Analysis-
10-KMar 30, 2026-
8-KFeb 27, 2026Analysis-
8-KFeb 23, 2026Analysis-
8-KFeb 19, 2026-
8-KFeb 13, 2026-
8-KJan 27, 2026-
8-KDec 23, 2025-

Related Health Care companies

All Health Care →

INMB SEC filings: frequently asked questions

Which institutions hold INMB stock?

As of September 30, 2026, the largest Inmune Bio, Inc. (INMB) holders among the 13F filers tracked by SignalX were Vanguard Capital Management LLC ($1.4 million), Morgan Stanley ($909,000), BlackRock ($638,000), Renaissance Technologies LLC ($581,000), Goldman Sachs Group ($314,000). 13F-HR reports are filed up to 45 days after each quarter ends.

What was INMB's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Inmune Bio, Inc. (INMB) reported revenue of $50,000 (up 257.1% from FY2024) and a net loss of $45.9 million. Diluted EPS was -$1.86. The figures come from the XBRL data in the 10-K.

What did INMB report in its latest 8-K?

Inmune Bio, Inc. (INMB) filed an 8-K on October 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 1.01 (Entry into a Material Definitive Agreement) and Item 3.02 (Unregistered Sales of Equity Securities). $4.50 million gross financing through 3,000,000 shares and warrants for 3,000,000 shares.

What are the latest INMB SEC filings?

Inmune Bio, Inc. (INMB) filed its latest 10-K annual report on March 30, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on October 29, 2026 and a Form 4 insider filing on September 23, 2026.

What is INMB's SEC CIK number?

Inmune Bio, Inc. (INMB)'s SEC Central Index Key (CIK) is 1711754. EDGAR lists every INMB filing under that number.

Ask anything about INMB

The research agent reads INMB's filings, financials, insider trades and 13F holders, then answers with sources.